(800) 424-6690

Spectrum Pharmaceuticals Securities Class Action

A class action lawsuit was recently filed against Spectrum Pharmaceuticals (NASDAQ: SPPI) on behalf of purchasers of Spectrum securities.

View our terms of service and privacy policy.

Lawsuit Eligibility

Spectrum Pharmaceuticals shareholders who purchased shares from March 17, 2022 through September 22, 2022.

Lead Plaintiff Deadline

September 24, 2025

About the Spectrum Pharmaceuticals Lawsuit

The class action lawsuit alleges that Spectrum made false or misleading statements to investors regarding its Pinnacle Study, a clinical trial involving poziotinib, a drug intended to treat certain lung cancer patients.

Spectrum shares were delisted following the Company’s merger with Assertio Holdings, Inc. (NASDAQ: ASRT).

Investors who purchased or acquired Spectrum Pharmaceuticals securities from March 17, 2022 through September 22, 2022, may no later than September 24, 2025, seek to be appointed as a lead plaintiff representative of the class.

Berger Montague has been a pioneer in shareholder litigation since its founding in 1970. The Firm has represented individual and institutional investors for over five decades and serves as lead counsel in courts throughout the United States.